Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
Immunic targets MS market with Phase 3 data - ICYMI
12:27pm, Saturday, 10'th Jan 2026
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's major milestones in 2025 and key expectations for 2026. He highlighted the significance of the phase 2 CALLIPER s
Immunic targets MS market with Phase 3 data - ICYMI
07:01am, Saturday, 10'th Jan 2026
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s major milestones in 2025 and key expectations for 2026. He...
Immunic looks to 2026 data as late-stage MS program advances
09:17am, Wednesday, 07'th Jan 2026
Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key clinical readouts that could shape its longer-te
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
06:30am, Wednesday, 07'th Jan 2026
– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus
Immunic looks to 2026 data as late-stage MS program advances
03:56am, Wednesday, 07'th Jan 2026
Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key...
Immunic (NASDAQ:IMUX) Shares Up 9.3% – Should You Buy?
02:11am, Tuesday, 06'th Jan 2026
Immunic, Inc. (NASDAQ: IMUX - Get Free Report)'s stock price rose 9.3% during mid-day trading on Monday. The company traded as high as $0.6529 and last traded at $0.6372. Approximately 1,596,354 share
Chimeric Therapeutics secures FDA Orphan Drug Designation for CHM CDH17 in gastric cancer
08:12am, Monday, 08'th Dec 2025
Chimeric Therapeutics Ltd (ASX:CHM, OTC:CHMMF) has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for its CHM CDH17 cell...
Immunic's long-term treatment hope for multiple sclerosis – ICYMI
08:29am, Saturday, 06'th Dec 2025
Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple sclerosis (MS). Speaking to Proactive, Chief Sci
Immunic’s long-term treatment hope for multiple sclerosis – ICYMI
03:04am, Saturday, 06'th Dec 2025
Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple...
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
06:30am, Wednesday, 26'th Nov 2025
NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal dise
Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI
09:34am, Saturday, 15'th Nov 2025
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's third quarter highlights, with a particular focus on the progress of its oral MS treatment, vidofludimus calcium.
Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI
04:28am, Saturday, 15'th Nov 2025
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s third quarter highlights, with a particular focus on the progress of...
Big Tech divisions widen as Amazon quietly backs tougher curbs on Nvidia’s China chip exports
02:56am, Friday, 14'th Nov 2025
Amazon.com Inc (NASDAQ:AMZN) reported support for the GAIN AI Act marks another turn in Washington’s increasingly fractious debate over how tightly to...
GlobalFoundries poised for cyclical recovery, share gains amid US onshoring push
10:30am, Thursday, 13'th Nov 2025
GlobalFoundries Inc (NASDAQ:GFS) is entering a period of accelerating momentum as it benefits from a cyclical recovery, US manufacturing onshoring, and...
Immunic advances MS program with key clinical findings in Q3
09:16am, Thursday, 13'th Nov 2025
Immunic Inc (NASDAQ:IMUX) highlighted positive clinical results for its lead drug candidate, vidofludimus calcium, showing statistically significant improvement in progressive multiple sclerosis (MS)
